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Abstract
Background. Molecular profiling allows tumor classification as well as assessment of diagnostic, prognostic, and 
treatment-related molecular changes. Translation into clinical practice and relevance for patients has not been 
demonstrated yet.
Methods. We analyzed clinical and molecular data of isocitrate dehydrogenase wild-type glioblastoma patients 
with sufficient clinical follow-up from the Heidelberg Neuro-Oncology Center and with molecular analysis of 
tumor tissue that consisted of DNA methylation array data, genome-scale copy number variations, gene panel 
sequencing, and partly mTOR immunohistochemistry between October 2014 and April 2018.
Results. Of 536 patients screened, molecular assessment was performed in 253 patients (47%) in a prospective 
routine clinical setting with further clinical appointments. Therapy decision was directly based on the molecular as-
sessment in 97 (38%) patients. Of these, genetic information from MGMT (n = 68), EGFR (n = 7), CDKN2A/B (n = 8), 
alterations of the PI3K–AKT–mTOR pathway (n = 5), and BRAF (n = 3) have been the most frequently used for de-
cision making with a positive overall survival signal for patients with glioblastoma harboring an unmethylated 
MGMT promoter treated according to the molecular assignment. Based on detected molecular alterations and 
possible targeted therapies, we generated an automated web-based prioritization algorithm.
Conclusion. Molecular decision making in clinical practice was mainly driven by MGMT promoter status in elderly 
patients and study inclusion criteria. A reasonable number of patients have been treated based on other molecular 
aberrations. This study prepares for complex molecular decisions in a routine clinical decision making.
Key Points
 • Molecular treatment decisions can be based on molecular profiling of recently obtained 
tissues.
Molecular profiling-based decision for targeted 
therapies in IDH wild-type glioblastoma
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The unfavorable prognosis of glioblastoma had not 
greatly improved in recent years since the introduction of 
radiochemotherapy.1 Advances in understanding of glioblas-
toma at the molecular level2–5 enable new opportunities for 
molecular diagnostics and targeted treatments of glioma 
patients. Molecular markers have been implemented in the 
updated World Health Organization (WHO) classification of 
brain tumors6 and are increasingly used to guide treatment 
decisions. Isocitrate dehydrogenase (IDH) 1 and 2 mutations7 
and 1p/19q co-deletion are routinely tested in glioma pa-
tients In addition, O6-methylguanine DNA methyltransferase 
(MGMT) promoter methylation status has been shown to 
be a predictive biomarker for response to alkylating che-
motherapy such as temozolomide or lomustine8,9 and was 
therefore integrated as predictive biomarker into the cur-
rent European guidelines for diagnosis and treatment of 
glioblastoma, for consideration at least in elderly patients.1 
At present, the MGMT promoter methylation status mainly 
guides treatment decisions in elderly patients in whom 
combined radiochemotherapy might be too burdensome 
due to age and comorbidities.10 Most other patients are still 
treated with radio-chemotherapy although patients with 
an unmethylated MGMT promoter are unlikely to benefit 
from temozolomide demonstrating the particular need for 
new treatment strategies in this patients’ subgroup, which 
was shown to not define a molecularly distinct subgroup.11 
Prior clinical trials demonstrated the feasibility of replacing 
temozolomide by targeted treatments (eg, temsirolimus, 
bevacizumab, or enzastaurin).12,13 These treatments did not 
result in worse survival outcome compared to temozolomide 
but also failed to improve survival in these molecularly un-
selected patient cohorts. Therefore, further clinical studies 
in molecularly selected patient populations may help to set 
the next steps. In non-IDH-mutant gliomas, targetable alter-
ations represent the variant III of epidermal growth factor re-
ceptor (EGFRvIII) mutation14 and v-Raf murine sarcoma viral 
oncogene homolog B (BRAF) mutations.15 Phosphorylation 
of mechanistic target of rapamycin (mTOR) at Ser2448 is 
suggested as a biomarker for response to treatment with 
temsirolimus12 and a hypermutator phenotype might predict 
response to checkpoint inhibition16 or not.17
The NCT Neuro Master Match (N2M2)/(Neurooncology 
Working Group of the German Cancer Society 
[NOA]-20) phase I/IIa umbrella trial intends to molecularly 
direct therapy for patients with glioblastoma harboring an 
unmethylated MGMT promoter. Allocation to specific tar-
geted treatments is based on molecular alterations.18 The 
feasibility to perform extensive molecular diagnostics in a 
timely fashion to inform clinical decision making was dem-
onstrated in the N2M2 pilot study.19 However, translation of 
extensive molecular diagnostic into clinical practice and 
resulting targeted treatments has not been demonstrated 
so far.
The aims of the present retrospective study were (1) to 
analyze the translation of prospective broad molecular 
diagnostics of IDH wild-type gliomas into clinical decision 
making and treatment with molecular-guided therapy in 
clinical routine, (2) to outline the current usage and poten-
tial for targeted therapies, and (3) to provide a web tool 




As of April 4, 2018, we screened the Heidelberg 
Neuropathology database. Clinical and molecular data of 
536 adult patients with the diagnosis of glioblastoma from 
the Heidelberg Neuro-Oncology Center with molecular 
analysis of tumor tissue consisting of at least methylation 
array allowing for assessment of global methylation pro-
files and copy number variations (CNVs) ± additional gene 
panel sequencing between October 2014 and April 2018 
were identified. The cohort was retrospectively revised for 
following inclusion criteria: (1) patients aged ≥18  years, 
(2) integrated diagnosis of IDH wild-type glioblastoma, (3) 
neuropathological report about results of molecular anal-
ysis available for treating physicians, and (4) further clinical 
appointments and treatment in the Department of Neuro-
Oncology after molecular analysis was reported. Two 
hundred fifty-three of the 536 patients (47%) were finally 
included in this study (Figure 1). The remaining excluded 
patients had either primarily research-related molecular 
Importance of the Study
The improvements in molecular profiling of 
glioblastoma allow personalized targeted treat-
ments based on detected molecular changes. 
This study demonstrated the translation of 
broad molecular assessment into molecular-
based treatments in a prospective clinical 
nonstudy setting. The molecular assessment 
was performed in 253 patients in a prospective 
routine clinical setting. Therapy decision was 
directly based on the molecular assessment 
in 97 of the patients and was mainly driven by 
MGMT promoter methylation status or genetic 
information from EGFR, CDKN2A/B, alterations 
of the PI3K–AKT–mTOR pathway, and BRAF. 
Revision of molecular data identified 213 po-
tentially targetable alterations in 183 of 253 
patients indicating that targeted treatments 
could increasingly influence clinical treatment 
decisions for future patients. A web-based ap-
plication was implemented to provide compre-
hensive information about possible treatment 
allocations based on individually uploaded 
molecular data to support complex molecular 
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analysis, were further treated outside Heidelberg, had an 
IDH mutated tumor or a non-glioma methylation classifier 
assignment (Figure 1). The concept of the investigation was 
approved by the local ethics committee (No. 206/2005).
Clinical characteristics of the patients were retrieved from 
electronic medical reports. The day of primary surgery was 
defined as the day of primary diagnosis. Follow-up was 
closed for included patients on October 1, 2019. Detected 
molecular alterations were obtained from neuropatholog-
ical reports and by retrospective analysis of raw data of re-
spective methylation and sequencing diagnostics.
Molecular Analysis
Molecular assessment was performed by the Department 
of Neuropathology, Heidelberg University Hospital. 
Besides confirmation of diagnosis, tissue was evaluated 
with a focus on tumor cell content (>40% needed) as well 
as necrosis. In parallel, blood was taken as germline con-
trol from suitable patients. Nucleic acid extraction from 
the tumor as well as blood control samples was performed 
using standard protocols (Maxwell 16 LEV Blood DNA 
Kit; Invitek Invisorb Genomic DNA Kit; Macherey Nagel 
NucleoSpin RNA Kit).
Illumina Methylation 450k/EPIC Array
For methylation arrays the Illumina HumanMethylation450 
(450k) or MethylationEPIC (EPIC) kits were used to obtain 
the DNA methylation status at >450 000 and >850 000 CpG 
sites, respectively, according to the manufacturer’s instruc-
tions at the Genomics and Proteomics Core Facility of the 
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German Cancer Research Center in Heidelberg, Germany 
and at the Department of Neuropathology as described 
previously.19
Methylation Data Processing and Copy Number 
Analysis
Raw methylation files were quality checked and methyl-
ation classifier assignment was performed (https://www.
molecularneuropathology.org).20 Samples were further ana-
lyzed using custom scripts based on the methylation pipeline 
“ChAMP” (version 2.10.1)21 in R (version 3.5.1, www.r-project.
org). In brief, filtering was done for multihit sites, SNPs, and 
XY chromosome-related CpGs, then data were normalized 
with a Beta-Mixture Quantile-based method and analyzed for 
batch effects with a singular value decomposition algorithm. 
MGMT promoter methylation status was determined by the 
method of Bady et al.22 Custom scripts based on the R pack-
ages “minfi” (version 1.26.2) and “conumee” (version 1.14.0) 
were implemented for CNV profiling and visualization. A pre-
defined set of 26 genes related to glioma characteristics or 
potential targeted treatment were annotated in detailed re-
gions and particularly analyzed.
Panel Sequencing of 130 Brain Tumor 
Relevant Genes
Panel sequencing of 130 genes was performed as de-
scribed previously.23 In brief, DNA was extracted from 
formalin-fixed paraffin-embedded tissue and blood if 
available and quality checked. Paired-end sequencing 
was performed on a NextSeq 500 instrument (Illumina). 
Subtraction of germline variants was performed whenever 
blood was available (34 of 110 patients, 30.9%).
For assessment of potentially targetable mutations, 
single-nucleotide variants (SNVs) were filtered by the 
snp138 database whenever germline subtraction from 
blood was not available. Further filtering was done in-
cluding only exonic alterations with either deletion/inser-
tion, nonsynonymous SNV or stop-gain SNV. Mutation 
allele frequency was calculated as follows: (altered reads)/
(all read at this position). Nonsynonymous SNV was 
tested for potential functional impact using the online tool 
mutationassessor.org.24
mTOR Immunohistochemistry
In 6 patients additional mTOR immunohistochemistry was 
performed as described previously using heat antigen re-
trieval procedure (citrate buffer) and the phospho-mTOR 
antibody (Ser-2448, #2976, Cell Signaling Technology, 
1:100) according to the manufacturer’s protocol.12 A scoring 
system was based on the percentage of p-mTOR positive 
tumor cells and their staining intensity. A score of 180 and 
above is considered a high mTOR phosphorylation.
Statistical Analysis and Prioritization Application
All computational and statistical analysis was done in R 
(version: 3.5.1, www.r-project.org) with the extension of 
open source packages. The prioritization application is 
coded with the “shiny” package (version 1.1.0) for R. Source 
code can be made available on reasonable request. 
Sequencing and copy number data are loaded from text 
files. Both sources are integrated and cross-checked with 
an exchangeable biomarker–drug combination table 
(Supplementary Table 4), taking also combinational bio-
markers and negative biomarkers that exclude the use of 
this drug into account. Targeted therapies with the highest 
evidence are presented. The prioritization application is 
freely available online (www.targetglioma.dkfz.de).
Results
Characteristics of the Patient Cohort
Two hundred fifty-three of 536 screened patients with de-
tailed molecular assessment were included in this study 
(Figure  1). Most patients (n = 238, 94%) were classified 
by methylation classification into the 3 main glioblas-
toma subgroups: receptor tyrosine kinase (RTK) I, RTK II, 
or mesenchymal (Supplementary Table 1). Fifteen patients 
belonged to rare IDH wild-type groups such as midline 
(n = 4), MYCN (n = 2), H3K27 mutant (n = 2), anaplastic ple-
omorphic xanthoastrocytoma (n = 1), anaplastic pilocytic 
astrocytoma (n = 1), and ganglioglioma (n = 1). In 3 pa-
tients, classification was not conclusive. The MGMT pro-
moter was methylated in 117 patients (46%), unmethylated 
in 135 patients (53%), and the methylation status was not 
determinable with certainty in one patient. One hundred 
ten patients (43%) were female and the median age at first 
diagnosis was 61.1  years (21–85  years) (Supplementary 
Table 1). Molecular assessment was performed in a pro-
spective routine clinical setting. Decisions to perform de-
tailed molecular analysis apart from routinely assessed 
MGMT methylation status to guide treatment decisions 
were made individually by treating physicians. Methylation 
arrays (450k or EPIC) were performed in all patients in-
cluded in this study. In 124 patients (49%) additional 
sequencing of predefined, potential targetable genes was 
carried out using a 130-gene panel sequencing23 approach 
(Figure  1 and Supplementary Table 2). Molecular assess-
ment was mainly performed with tumor tissues from pri-
mary tumors (234 patients, 92%) whereas tumor tissues 
from re-resection of recurrent tumors were used in 19 pa-
tients (8%).
Molecular-Guided Decisions
Decisions to perform detailed molecular analysis were 
mostly made before or during first-line therapy (in 212 pa-
tients, 84%) guiding first-line treatment or evaluating pos-
sible treatment strategies in case of progression. However, 
in 41 patients (16%), decisions for molecular analysis 
were taken after progressive disease to investigate treat-
ment options for recurrent tumors (Supplementary Table 
2). Molecular assessments resulted in a molecular-guided 
therapy in 97 of the 253 patients (38%) (Supplementary 
Table 2). Fifty-six of the 124 patients (45%) with molecular 
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and 41 of the 129 patients (32%) with molecular analysis 
including methylation array without further sequencing re-
ceived treatment guided by detected molecular alterations. 
However, treatment decisions were mostly based on data 
obtained from methylation array (methylation and CNV) or 
occasionally performed immunohistochemistry of mTOR 
phosphorylation (3%). Panel sequencing was used to allo-
cate patients with targetable BRAF V600E mutations (3%) 
and EGFR mutation (1%).
Molecular analysis frequently guided treatments at first-
line therapy (in 72 patients, 74%, Supplementary Table 2). 
Twenty-five patients (26%) received molecular-guided 
treatments at progressive disease. In these patients, the 
molecular assessment was performed with tissue from pri-
mary resection in 17 patients (68%) and with freshly dis-
sected tissue from re-resection of recurrent tumors in 8 of 
these patients (32%) (Supplementary Table 1).
Molecular-guided treatment decisions were based on 
MGMT methylation status in 68 patients (70%). MGMT 
methylation status was mostly used to guide first-line 
therapy in elderly patients toward a monotherapy with 
temozolomide in case of methylated MGMT promoter 
or toward radiotherapy in patients with unmethylated 
MGMT promoter due to the presumed limited efficacy of 
temozolomide in the latter patient group.9,10,25,26 In 10 pa-
tients, decisions about treatments with bevacizumab and 
nivolumab, for which no generally accepted biomarker 
exists so far, were mostly based on an unmethylated 
MGMT promoter providing alternative treatment op-
tions for patients not likely benefitting from alkylating 
chemotherapy.
Apart from MGMT promoter status, genetic information 
about EGFR, CDKN2A/B, and BRAF was most frequently 
used for clinical decision making (Table 1). The detection 
of an EGFR amplification or mutation resulted in EGFR in-
hibitor treatment strategies in 7 patients and the detection 
of CDKN2A/B deletions in treatments with the CDK4/6 in-
hibitor palbociclib in 8 patients. Three patients with BRAF 
V600E mutations received further targeted treatment with 
dabrafenib and trametinib. In addition, H3K27M muta-
tions, PDGFR amplifications, PTEN status, NF1 mutation, 
and the phosphorylation of mTOR at Ser2448 were used 
for molecular-guided treatment decisions. The detection of 
an H3K27M mutation led to treatment with panobinostat 
in one patient. One patient was treated with imatinib 
based on PDGFR amplification and 2 patients were treated 
with the PI3K inhibitor Buparlisib and the cMET inhibitor 
INC280 based on negative PTEN status. Pembrolizumab 
was added to first-line therapy in one patient due to the de-
tection of a hypermutator phenotype. The phosphorylation 
of mTOR resulted in treatments with the mTOR inhibitor 
temsirolimus in 4 patients.12 In addition, one patient was 
treated with temsirolimus based on a PIK3CA mutation and 
one patient received further treatment with the MEK inhib-
itor trametinib based on the detection of an NF1 mutation.
Molecular-guided treatments were initiated after a me-
dian of 29.5  days (range: 11–88) after primary diagnosis 
in patients receiving molecular-guided treatments as 
first-line therapy and after a median of 600 days (range: 
112–2735) in patients with molecular-guided treatments at 
recurrent disease. In the group of patients with molecular-
guided treatments at recurrent disease, 40% of these 
patients (10 of 25)  received molecular-guided treatments 
after first progression, 36% (9) of these patients after 
second progression, and 24% (6) of these patients were 
treated with molecular-guided treatments after more than 
2 prior progressions (2 patients after third progression, 
3 patients after fourth progression, and one patient after 
fifth progression). All of these patients were treated with 
radiotherapy and all but one patient additionally with 
temozolomide chemotherapy prior to molecular-guided 
treatments. Forty-four percent (11) of the patients received 
further chemotherapy with lomustine at progressive dis-
ease prior to initiation of molecular-guided treatments. 
The median Karnofsky performance score (KPS) at the 
start of molecular-guided treatments was 80% (range: 
60%–100%). The overall survival (OS) was similar in the 
patients’ groups with and without molecular-guided treat-
ments with a median of 416  days in patients with and 
414 days in the patients without molecular-guided treat-
ments, with a high rate of censored patients (32 patients 
[33%] and 49 patients [31%], respectively). For further sur-
vival analysis, only patients with treatments based on mo-
lecular alterations other than MGMT methylation status 
were compared with the patients without molecular-based 
treatments. Patients with molecular-guided treatments 
based on MGMT methylation status were excluded from 
further survival analysis as this patients’ subgroup mostly 
consisted of elderly patients who received either mono-
therapy with temozolomide or monotherapy with radio-
therapy and were therefore not comparable with the other 
patients. After stratification for MGMT promoter status, 
there was a prolonged OS with molecular-based treat-
ments in patients with tumors harboring an unmethylated 
MGMT promoter, whereas this effect on OS was not ob-
served in patients with glioblastomas harboring a methyl-
ated MGMT promoter (Supplementary Figure 1).
Patient Examples
An 81-year-old patient was diagnosed with a right tem-
poral glioblastoma in February 2017. Molecular diag-
nostics revealed an IDH wild-type glioblastoma with an 
unmethylated MGMT promoter, the patient was treated 
with radiotherapy alone as a first-line treatment after 
tumor resection in March 2017. First disease progression 
occurred in December 2018. Then re-radiotherapy and 
temozolomide chemotherapy were discussed as further 
treatment options and the decision for a re-radiotherapy 
was made. Re-radiotherapy was performed in January 
2019. However, the patient died in March 2019.
A 54-year-old patient was diagnosed with a right parieto-
occipital glioblastoma in April 2015. Molecular diagnos-
tics demonstrated an IDH wild-type glioblastoma with 
an unmethylated MGMT promoter, phosphorylation of 
mTOR at Serin2448, a CDK4 and MDM2 amplification, 
and a deletion of CDKN2A. The patient was treated with 
combined radiochemotherapy with temozolomide and 
adjuvant temozolomide treatment. After disease progres-
sion in October 2015, the decision for a treatment with 
temsirolimus was made based on the phosphorylation 
of mTOR at Serin2448. Temsirolimus was given until fur-







niversitatsbibliothek user on 03 Septem
ber 2020
 6 Kessler et al. Molecular profiling-based decision
treatment with bevacizumab was initiated due to the pre-
sumed limited efficacy of further alkylating chemotherapy 
based on the unmethylated MGMT promoter. However, 
in March 2016 MRI revealed further disease progression. 
Based on the detected molecular alterations with a CDK4 
amplification and deletion of CDKN2A, a treatment with 
palbociclib was initiated and given until progressive dis-
ease in August 2016, which was also the last consultation 
in our department. At this time a recommendation for fur-
ther treatment with lomustine was made.
Hypothetic Allocation to Targeted Treatments 
Based on Automated Allocation
Future studies for targeted therapies aim to include a 
broader range of patients based on molecular profile. We 
aimed at identifying patients in our cohort for possible 
treatment allocation. CNV profiling from methylation array 
(100% of cases) identified amplifications of EGFR in 116 
patients (46%). Less common amplifications occurred in 
PDGFRA, MYCN, CDK4, and MDM2. Most frequent dele-
tions have been observed in CDKN2A/B (58%), NF1 (18%), 
and PTEN (12%) (Figure  2A). One hundred thirty-gene 
panel sequencing identified 305 SNVs and insertions/dele-
tions in 91 of the 110 (83%) profiled tumors (mean: 3.42, 
range 0–43). We additionally assessed mutation allele fre-
quency and potential impact of the mutation on protein 
function with mutationassessor.org.24 PTEN mutations or 
frameshift deletions were detected in 35 patients (32%) 
and TP53 mutations and mutations of EGFR in 18% and 
9% of patients, respectively. Twenty mutations (7%) were 
rated as potentially high impact on protein function, of 
these have been 8 PTEN and 3 EGFR mutations (Figure 2B 
and Supplementary Table 3). Two of the patients had >15 
mutations in 130-gene panel sequencing, suggesting a hy-
permutation phenotype. An updated treatment allocation 
algorithm (www.targetglioma.dkfz.de) based on our recent 
suggestion27 was implemented and used to identify puta-
tive biomarkers (Figure 3 and Supplementary Table 4). This 
application is currently capable of calculating potential 
targets from the combination of methylation, sequencing, 
and p-mTOR immunohistochemistry data as used in the 
N2M2 trial.28 Resistance biomarkers (eg, RB mutation for 
CDK4/6 inhibition) are included. It will be constantly up-
dated according to new knowledge and to the capability 
  
Table 1. Molecular-Guided Treatment Decisions
Molecular-Guided Therapy (n = 97)
Molecular alterations for decision of molecular-guided therapy 97
 MGMT (methylated/unmethylated) 68 (31/37)
 BRAF V600E mutation 3
 EGFR amplification/EGFRvIII mutation 7
 CDKN2A/B deletion 8
 H3K27M mutation 1
 Hypermutated phenotype 1
 phospho-mTOR Ser2449 4
 PIK3CA mutation 1
 PTEN negative 2
 PDGFR amplification 1
 NF1 mutation 1
Targeted therapy  
 Palbociclib 8
 EGFR inhibitor 7







 Buparlisib (PI3K inhibitor), INC280 (cMET inhibitor) 2
 Imatinib 1
KPS prior to start of targeted therapies (median; range) 80 (60–100)
Detected molecular alterations, its frequency, and guided molecular treatments are listed in this table. In addition, Karnofsky Performance Scores 
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Figure 2. Genetic alterations in the patient cohort. (A) Copy number alterations derived from 450k/EPIC methylation array of 26 frequently altered 
glioblastoma relevant genes in the 253 patients. (B) Oncoplot of the panel sequencing derived mutations in the cohort with sequencing data. The 
top 40 most frequent mutations in the cohort are shown. APA, anaplastic pilocytic astrocytoma; MES, mesenchymal; RTK, receptor tyrosine ki-
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of including all kinds of multiomic data including whole 
genome sequencing, expression, and proteomic data. 
According to the current application, we identified 213 
potentially targetable alterations in 183 of the 253 pa-
tients (72%, Figure 4). Most of the alterations might confer 
sensitivity to a CDK4/CDK6 inhibitor with a lower con-
fidence level. Also, higher confidence (2B) BRAF V600E 
mutations have been detected in 2 cases. We furthermore 
detected 2 mutations and one non-frameshift substitu-
tion in the ALK gene, but the impact of these mutations 
  
























Figure 4. Distribution of potentially targetable alterations. Potentially targetable alterations grouped by potential treatment are shown for 183 
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is unknown and allele frequencies only range from 32% 
to 47% (Figure  2B, Supplementary Table 4), questioning 
the usability of ALK mutations in treatment decision for 
glioma. Of note, 9 of the 110 patients with panel sequencing 
harbored NF1 frameshift deletions or stop-gain SNVs po-
tentially sensitizing for MEK and mTOR inhibitors with al-
lele frequencies between 30% and 100%.
Patients With Multiple Molecular Targets and 
Possibilities for Combined Therapies
As single targeted therapies are unlikely to promote du-
rable responses, we aimed to identify possible combination 
therapies. Twenty-seven patients (11%) of our cohort had 2 
targetable alterations. Most frequent co-occurring target-
able alterations were CDK4 amplifications or CDKN2A/B 
co-deletions in combination with MDM2 amplifications (in 
12 patients), which might predict a response to treatments 
with palbociclib and idasanutlin, respectively. In addition, 
CDKN2A/B co-deletions were detected in combination 
with NF1 deletions/mutations, suggesting a response to 
MEK/CDK4/6 inhibitor treatment strategies, in 3 patients 
and in combination with TSC2 mutations, which might in-
dicate a response to treatment with temsirolimus in one 
patient. Moreover, in 5 patients, CDKN2A/B co-deletions 
co-occurred with CDK4 or CDK6 amplifications, which 
might predict a response to treatment with a CDK4/6 inhib-
itor (Figures 3 and 4).
Discussion
Comprehensive molecular assessment was performed in 
253 patients in a prospective clinical routine setting leading 
to molecular-guided treatments in a reasonable number of 
these patients (97 patients, 38%).
Molecular-guided treatments were frequently based on 
MGMT methylation status guiding treatment decisions at 
first-line therapy in elderly patients and thereby following 
the European guidelines for the treatment of glioblastoma 
in this patients’ group.1 In addition, the MGMT promoter 
status was used for treatment decisions of therapies with 
so far unknown biomarkers such as bevacizumab and 
nivolumab to provide treatment alternatives for patients 
not likely benefitting from alkylating chemotherapy. Apart 
from MGMT promoter status, alterations in EGFR, BRAF 
mutations, CDKN2A/B co-deletions, and phosphoryla-
tion of mTOR at Ser2448 were most frequently used for 
molecular-guided treatment decisions. Molecular-guided 
treatments at first-line therapy were mainly based on 
MGMT methylation status or molecular alterations used 
as study inclusion criteria. Decisions for targeted treat-
ments based on other genetic alterations were mostly 
taken at progressive disease as these treatments do not 
represent standard therapy and treatment costs have to 
be applied for at medical insurances. However, along with 
further improvements of molecular diagnostics, increasing 
translation of molecular alterations into molecular-guided 
treatment decisions, and data about the effectivity of 
targeted therapies, these treatments might be better 
assessable also for treatments in the early stage of disease 
in near future. In this context, one limitation of this study 
is that it was not meant and powered for survival analysis. 
Survival analysis for patients with molecular-guided treat-
ments based on molecular alterations other than MGMT 
promoter status suggested that particularly patients with 
an unmethylated MGMT promoter had a longer OS if 
molecular-guided treatments were used. However, the pa-
tient population might be biased by patients’ selection for 
extensive molecular analysis and various treatments had 
been administered in different disease stages. In addi-
tion, interpretation of survival data is limited due to small 
numbers of patients with molecular-guided treatments in 
the patients’ subgroup for survival analysis, the different 
molecular-guided treatments, and the retrospective na-
ture of the study. In this regard, the recently started N2M2 
trial will provide important data about the effectivity of 
molecular-guided targeted therapies in first-line treatment. 
Until that, this current study offers an exploratory ap-
proach to the current use of targeted drugs and the usage 
of molecular data. Others have conducted similar trials 
with a focus on repurposed drugs and the option for mul-
tiple therapies at recurrence.29
Although a reasonable number of patients have already 
received treatments based on molecular markers in clinical 
practice beyond MGMT promoter methylation status for 
chemotherapy decision, we identified targetable alterations 
in many more patients (29 vs. 185 patients) demonstrating 
that personalized treatments are just at the beginning 
to influence clinical decision making. Nevertheless, at 
present molecular-guided treatments based on molecular 
markers other than MGMT promoter remain as treatment 
options for recurrent disease due to the limited accessi-
bility at the early stage of disease outside clinical studies. 
Therefore, patients were treated with molecular-guided 
treatments only at the late stages of disease in this study 
limiting the efficacy of the treatments and its translation 
into clear survival benefits. Furthermore, patients need to 
have a reasonable KPS prior to treatment initiation and 
also after (multiple) progressions, which limits the poten-
tial for molecular-guided treatments to a small subgroup 
of patients. Therefore, studies demonstrating the feasibility 
of molecular-guided treatment decisions and its transla-
tion into clinical practice help to increase the accessibility 
of targeted treatments at an early stage of the disease also 
outside of clinical trials. In this regard, it is important to se-
lect targeted treatments with a presumed high blood–brain 
barrier penetration to ensure that the treatment is reaching 
its target.
However, molecular-guided clinical decision making re-
mains challenging as molecular analysis often results in 
the detection of several potential targetable alterations 
with many options for single or combined treatments and 
clinical data providing evidence for the efficacy of different 
molecular-guided treatments in selected patients’ popu-
lations are still missing. In this regard, the N2M2 trial will 
provide important information in the upcoming years. 
The prioritization algorithm is helpful in guiding treat-
ment allocations to single targeted treatments based on 
the level of evidence for respective biomarkers and treat-
ments. However, in cases with the detection of several 
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therapy with multiple targeted treatments might be even 
more effective especially with regard to acquired resist-
ance mechanisms. We identified 30 patients in our cohort 
who had at least 2 potentially targetable molecular alter-
ations. Among them, CDK4 and MDM2 amplifications were 
the most frequently detected co-occurring alterations that 
are targetable by palbociclib and idasanutlin. In addition, 
NF1 deletion, which might predict a particular response 
to MEK inhibitors, was frequently found in combination 
with CDKN2A/B deletion, which might predict response to 
palbociclib. One patient displayed CDK4 and MDM2 ampli-
fication as well as a nonsynonymous SNV in the NF1 gene. 
Therefore, treatments with palbociclib, idasanutlin, or MEK 
inhibitors might represent effective treatment options for 
this patient. Based on recent preclinical studies, combined 
treatment of idasanutlin and MEK inhibition demonstrated 
superior efficacy than respective monotherapies.30 In ad-
dition, MEK inhibition was demonstrated to be effective in 
tumors with NF1 loss.31,32 Thus, it could be speculated that 
the combination of idasanutlin with a MEK inhibitor could 
be the better choice over a combination with a CDK4 inhib-
itor for this patient. These data also demonstrate the chal-
lenge of molecular-guided clinical decision making and the 
urgent need for further data about the effectivity and toler-
ability of combined treatments. In addition, co-occurrences 
of CDK4 or CDK6 amplification and CDKN2A/B co-deletion, 
which both represent potential biomarkers for treatment 
with palbociclib, were detected in 6 patients. As alterations 
of multiple genes of the same pathway might lead to 
higher confidence in the prediction of potential response 
to targeted therapies, further molecular understanding of 
altered pathways will improve the prediction of treatment 
efficacy in the near future.
In conclusion, the data demonstrate that broad molecular 
assessment already led to molecular-guided treatments 
in a reasonable number of patients in prospective clin-
ical nonstudy settings. Molecular decision making in clin-
ical practice was mainly driven by MGMT promoter status 
in elderly patients or study inclusion criteria for first-line 
therapy and by detection of various molecular alterations 
at the treatment of recurrent disease. In addition, revision 
of molecular data identified relevantly more patients with 
potentially targetable alterations indicating that targeted 
treatments could increasingly influence clinical treatment 
for future patients. To support molecular clinical decision 
making, we implemented a web application providing 
comprehensive information about possible treatment al-
locations based on individually uploaded molecular data. 
This tool will be constantly updated and further developed 
based on the newest clinical and preclinical findings and 
integration of a broad range of multiomics data will be per-
formed. This study complements the molecular N2M2 pilot 
study in a routine clinical decision making and prepares 
for complex molecular decision making for glioblastoma 
patients.
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